Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Announces Pricing of Public Offering of Common Shares
Uplisted to NASDAQ Global Market Under Symbol "RTRX" NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX)(formerly OTCQB:RTRX) today announced the pricing of an underwritten public offering of 4,705,882 shares of its common stock, offered at a price of $8.50 per share.
View HTML
Toggle Summary Retrophin Announces Public Offering of Common Stock
NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) today announced that it has commenced an offering to sell $40,000,000 of shares of its common stock in a proposed underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to
View HTML
Toggle Summary Retrophin Unveils New Clinical Development Candidate RE-034, An ACTH Analog
Company to Initiate Clinical Development in Multiple Indications Management to Host Conference Call and Webcast Tomorrow at 9:00 a.m. ET NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced its newest clinical development candidate RE-034 (cosyntropin), a long-acting synthetic
View HTML
Toggle Summary Retrophin Withdraws Offer for Transcept Pharmaceuticals
NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) today announced that it has withdrawn its offer to acquire all of the shares of Transcept Pharmaceuticals, Inc.'s common stock for $4.00 per share in cash. Retrophin is no longer a shareholder of Transcept.
View HTML
Toggle Summary Retrophin Announces Agreement to Acquire Kyalin Biosciences
Acquisition expands Retrophin's CNS Pipeline NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it will acquire privately-held Kyalin Biosciences, Inc. , an early-stage company based in San Diego, CA , that is developing therapies targeting the core symptoms of autism
View HTML
Toggle Summary Retrophin to Co-Sponsor Clinical Trial of Intranasal Oxytocin for Schizophrenia
  Data will support company's clinical development program of Syntocinon ™ for the treatment of schizophrenia NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) announced that it has agreed to support Phase II clinical trial of oxytocin for the treatment of schizophrenia
View HTML
Toggle Summary Retrophin Signs U.S. License Agreement for Syntocinon™ Nasal Spray (Oxytocin)
Retrophin to reintroduce Syntocinon™ Nasal Spray in the U.S. and Develop the Drug for Schizophrenia and Autism Management to Host Conference Call and Webcast Today at 5:30 p.m. ET NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) today announced that it has signed an agreement with
View HTML
Toggle Summary Retrophin, Inc. Reports Third Quarter 2013 Operational and Financial Results
Conference Call/Webcast to be held Today, November 18, 2013 at 4:30 PM EST
View HTML
Toggle Summary Retrophin, Inc. Announces New Hires
Building Senior Team for Expansion Phase
View HTML
Toggle Summary Retrophin, Inc. to Hold Third Quarter Operational and Financial Results Conference Call On Monday, November 18, 2013 at 4:30pm EST
NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) announced today that management will host a conference call and webcast, to discuss its operational and financial results for the period ended September 30, 2013 , on Monday, November 18, 2013 at 4:30pm EST .
View HTML